The number of new COVID-19 cases in the U.S. is dropping as the omicron wave wanes in many places, but some parts of the country lag behind.
"As a nation, it looks like we've kind of gotten to the peak and are now starting on the decline, but it's very uneven," explains Dr. Gregory Poland, head of Mayo Clinic's Vaccine Research Group. "That's what's happening in the big Northeast cities, and maybe in L.A., for example. But if you look at the rest of the nation, it's not clear that they have peaked yet."
And on the heels of the latest surge, a new omicron subvariant — BA.2 — is emerging. Early indications are that the new subvariant may be more transmissible, but it does not appear to cause more severe disease than the original omicron strain.
Mayo experts, including Dr. Poland, continue to urge COVID-19 vaccinations and boosters as the best defense against the latest variants.
"By getting two doses of vaccine and a booster, or a dose of Johnson & Johnson and a booster, you move yourself into a category of maximal protection such that if you have a normal immune system, you are probably going to have trivial or even asymptomatic disease if you get infected with COVID-19," explains Dr. Poland.
On the Mayo Clinic Q&A podcast, Dr. Poland discusses the latest information on COVID-19 and answers listener questions.
_______________________________________
For the safety of its patients, staff and visitors, Mayo Clinic has strict masking policies in place. Anyone shown without a mask was either recorded prior to COVID-19 or recorded in a nonpatient-care area where social distancing and other safety protocols were followed.
Information in this post was accurate at the time of its posting. Due to the fluid nature of the COVID-19 pandemic, scientific understanding, along with guidelines and recommendations, may have changed since the original publication date.
Dr. Poland has served as a consultant for Merck & Co. Inc., Medicago Inc., GlaxoSmithKline plc, Sanofi Pasteur, Emergent BioSolutions Inc., Dynavax Technologies Corp., Genentech Inc., Eli Lilly and Co., Janssen Pharmaceuticals Inc., Kentucky BioProcessing Inc. and Genevant Sciences Corp. Honoraria: Elsevier.
For more information and all your COVID-19 coverage, go to the Mayo Clinic News Network and mayoclinic.org.
Learn more about tracking COVID-19 and COVID-19 trends.
"As a nation, it looks like we've kind of gotten to the peak and are now starting on the decline, but it's very uneven," explains Dr. Gregory Poland, head of Mayo Clinic's Vaccine Research Group. "That's what's happening in the big Northeast cities, and maybe in L.A., for example. But if you look at the rest of the nation, it's not clear that they have peaked yet."
And on the heels of the latest surge, a new omicron subvariant — BA.2 — is emerging. Early indications are that the new subvariant may be more transmissible, but it does not appear to cause more severe disease than the original omicron strain.
Mayo experts, including Dr. Poland, continue to urge COVID-19 vaccinations and boosters as the best defense against the latest variants.
"By getting two doses of vaccine and a booster, or a dose of Johnson & Johnson and a booster, you move yourself into a category of maximal protection such that if you have a normal immune system, you are probably going to have trivial or even asymptomatic disease if you get infected with COVID-19," explains Dr. Poland.
On the Mayo Clinic Q&A podcast, Dr. Poland discusses the latest information on COVID-19 and answers listener questions.
_______________________________________
For the safety of its patients, staff and visitors, Mayo Clinic has strict masking policies in place. Anyone shown without a mask was either recorded prior to COVID-19 or recorded in a nonpatient-care area where social distancing and other safety protocols were followed.
Information in this post was accurate at the time of its posting. Due to the fluid nature of the COVID-19 pandemic, scientific understanding, along with guidelines and recommendations, may have changed since the original publication date.
Dr. Poland has served as a consultant for Merck & Co. Inc., Medicago Inc., GlaxoSmithKline plc, Sanofi Pasteur, Emergent BioSolutions Inc., Dynavax Technologies Corp., Genentech Inc., Eli Lilly and Co., Janssen Pharmaceuticals Inc., Kentucky BioProcessing Inc. and Genevant Sciences Corp. Honoraria: Elsevier.
For more information and all your COVID-19 coverage, go to the Mayo Clinic News Network and mayoclinic.org.
Learn more about tracking COVID-19 and COVID-19 trends.
- Category
- Management
Be the first to comment